Document Type

Article

Publication Date

2-27-2013

Keywords

Patient Protection and Affordable Health Care Act, Physician Payment Sunshine Act

Comments

"Republished with the permission of the Food and Drug Law Institute (FDLI)."

Abstract

This [article] explains the requirements under the Patient Protection and Affordable Health Care Act’s Physician Payment Sunshine Act that all medical product manufacturers report to Health and Human Services (HHS) any payment or transfer of value made to physicians and teaching hospitals. Author Abraham Gitterman ... warns that manufacturers may face adverse consequences of public access to payment data, including fraud and abuse investigations and private litigation actions. He recommends that manufacturers begin training employees to ensure compliance with the statute and reduce the likelihood of further investigations. He further suggests that the Center for Medicare & Medicaid Services (CMS) include contextual information about physician-industry relationships when making payments public in order to minimize harming the reputations of physicians. Gitterman concludes that if CMS’ implementation of the Sunshine Act stigmatizes collaborations between physicians and industry, medical progress will be slowed and patients will be harmed.

Disciplines

Food and Drug Law

Recommended Citation

3 Food and Drug Policy Forum 1 (no. 4, 2013).

Share

COinS